To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Inspire Medical Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INSPNovember 13, 2025 5:57 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 13, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 20 ...

Owlet (NYSE:OWLT) Q3 2025 Earnings Call November 13, 2025 04:30 PM ET Speaker1Good afternoon. Thank you for attending the Owlet Q3 2025 earnings conference call. My name is Matt, and I'll be the moderator for today's call. All lines will be muted during the presentation portion of the call, with an opportunity for questions and answers at the end. If you would like to ask a question, please press star one on your telephone keypad. I'll now pass the conference over to our host, Jay Gentzkow, Investor Relatio ...

Trisalus Life Sciences (NasdaqGM:TLSI) Q3 2025 Earnings Call November 13, 2025 04:30 PM ET Speaker1Afternoon and welcome to Trisalus Life Sciences' third quarter 2025 earnings conference call. Currently, all participants are on a listen-only mode. Following management's prepared remarks, we will hold a question-and-answer session. As a reminder, this call is being recorded for replay purposes. I will now turn the call over to Jeremy Pfeffer, Managing Director with Life Sciences Advisors. Please go ahead, si ...

RenovoRx (NasdaqCM:RNXT) Q3 2025 Earnings Call November 13, 2025 04:30 PM ET Speaker6Be a conference call operator today. Please note that today's call is being recorded, and all participants other than management are in listen-only mode. There will be a Q&A session following the management's presentation. I will now turn the call over to Walter Pinto, Managing Director of KCSA Strategic Communications. Please go ahead. Thank you.Speaker0Thank you, Operator. Good afternoon, everyone, and welcome to RenovoRx ...

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Inspire Medical SystemsNovember 13, 2025 5:29 PM EST | Source: Faruqi & Faruqi LLPFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inspire Medical To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Inspire Medical between August 6, 2024 and August 4, 2025 and would like to discuss your legal rig ...

IRVINE, CA / ACCESS Newswire / November 13, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it has received an unfavorable decision from the U.S. Food & Drug Administration ("FDA") in response to its supervisory appeal of the not-approvable letter it received on August 19, 2025 in response to its Premarket Approval (PMA) application for VenoValve®, a surgical replacement veno ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Zimmer Biomet Holdings, Inc. ("Zimmer†or the "Company†) (NYSE: ZBH) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ZIMMER BIOMET HOLDINGS, INC. (ZBH), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your lega. ...

Law Offices of Howard G. Smith Encourages Inspire Medical Systems, Inc. (INSP) Shareholders To Inquire About Securities Fraud Class Action Share Nov 13, 2025 4:39 PM Eastern Standard Time 19020Telephone: (215) 638-4847Email: howardsmith@howardsmithlaw.comVisit our website at: www.howardsmithlaw.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class a ...

融资概况 - 公司宣布获得总额高达7700万美元的融资承诺，以推动其Genio系统在美国的商业化[1] - 融资组合包括私募股权配售、注册直接发行以及可转换债券[1][2] - 融资总额包括2200万欧元的私募、560万美元的注册直接发行以及最高4500万欧元的可转换债券融资[2] 私募股权配售详情 - 私募发行5,481,678股新股，认购价格为每股4.00欧元，总收益为2200万欧元（约合2500万美元）[3] - 私募预计于2025年11月17日左右完成，受惯例成交条件约束[3] - 投资者包括公司董事长、管理层以及行业巨头Cochlear和Resmed[1][13] 注册直接发行详情 - 注册直接发行1,215,964股新股，每股价格为4.6304美元，总收益约为560万美元[5] - 此次发行基于一份有效的F-3表格货架注册声明[6] - 发行预计于2025年11月18日左右完成，受惯例成交条件约束[5] 可转换债券融资详情 - 与一家国际金融服务公司签订认购协议，发行最高本金总额为4500万欧元（约合5200万美元）的可转换债券[7] - 融资分为两期：第一期最高2250万欧元，公司有权在首期结束后七个月起的30天内，在满足特定条件下发行第二期2250万欧元[7] - 第一期债券预计于2025年12月完成，发行价格为面值的92%，年利率为6.5%，按季付息，期限为三年[7] - 第一期债券的默认转换价格为5.00欧元，相当于私募发行股票价格的125%[7] 融资资金用途 - 净收益将用于支持Genio系统在美国的商业化活动，并推进在美国以外初始目标市场的商业化[8] - 资金将用于继续收集临床数据，支持医生发起的阻塞性睡眠呼吸暂停患者治疗相关临床研究项目[8] - 部分资金将用于资助与Genio系统升级、产品可制造性重新设计及降本计划相关的研发活动[8] - 资金还将用于继续构建新技术管线，探索在阻塞性睡眠呼吸暂停监测和诊断领域的潜在合作机会[8] - 剩余资金将用于一般公司用途，包括营运资金、资本支出、投资及潜在收购[8] 公司背景与产品 - 公司是一家医疗技术公司，专注于开发和商业化创新解决方案，通过神经调节治疗阻塞性睡眠呼吸暂停[10] - 核心产品Genio系统是一种以患者为中心、无导线、无电池的舌下神经刺激疗法，用于治疗阻塞性睡眠呼吸暂停[10] - Genio系统已于2019年获得欧洲CE标志，并于2025年8月获得美国FDA批准作为处方设备[11][12] - 公司已完成两次首次公开募股：2020年9月在布鲁塞尔泛欧交易所上市，2021年7月在纳斯达克上市[11]